Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.

Cellular and Molecular Mechanisms of Metformin Action

Open access
LaMoia, Traci E, Shulman, Gerald I · 2021 · Endocrine Reviews

Abstract

Metformin is a first-line therapy for the treatment of type 2 diabetes, due to its robust glucose-lowering effects, well-established safety profile, and relatively low cost. While metformin has been shown to have pleotropic effects on glucose metabolism, there is a general consensus that the major glucose-lowering effect in patients with type 2 diabetes is mostly mediated through inhibition of hepatic gluconeogenesis. However, despite decades of research, the mechanism by which metformin inhibits this process is still highly debated. A key reason for these discrepant effects is likely due to the inconsistency in dosage of metformin across studies. Widely studied mechanisms of action, such as complex I inhibition leading to AMPK activation, have only been observed in the context of supra-pharmacological (>1 mM) metformin concentrations, which do not occur in the clinical setting. Thus, these mechanisms have been challenged in recent years and new mechanisms have been proposed. Based on the observation that metformin alters cellular redox balance, a redox-dependent mechanism of action has been described by several groups. Recent studies have shown that clinically relevant (50-100 μM) concentrations of metformin inhibit hepatic gluconeogenesis in a substrate-selective manner both in vitro and in vivo, supporting a redox-dependent mechanism of metformin action. Here, we review the current literature regarding metformin's cellular and molecular mechanisms of action.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endrev/bnaa023

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1. Regulation of hepatic gluconeogenesis. Hepatic gluconeogenesis is regulated through allostery, substrate availability, redox balance, and gene expression. WAT lipolysis produces glycerol and NEFA, which can both independently stimulate hepatic gluconeogenesis. NEFA enters mitochondrial β-oxidation which produces acetyl-CoA, an allosteric activator of PC. PC catalyzes the conversion of pyruvate to oxaloacetate, which can directly enter the gluconeogenic pathway. On the other hand, glycerol is itself a gluconeogenic substrate. Glycerol from WAT lipolysis is phosphorylated to G3P and converted to DHAP, a gluconeogenic intermediate, by GPD2. The reaction catalyzed by GPD2 is dependent on cellular redox state and is inhibited by a high [NADH]:[NAD+] ratio. Similarly, gluconeogenesis from lactate is redox-regulated, because the conversion of lactate to pyruvate by LDH is inhibited by a high [NADH]:[NAD+] ratio. Transcriptional regulation of PCK1 and G6PC is coordinated by the opposing actions of glucagon and insulin. When insulin binds its receptor, AKT is activated and promotes nuclear exclusion of FOXO1, which decreases gluconeogenic gene expression. In contrast, glucagon binds the glucagon receptor and promotes IP3R-I-mediated ER Ca++ release. This in turn activates CRTC2, which forms a complex with CREB and CBP, and promotes transcriptional upregulation of PCK1 and G6PC. Abbreviations: CBP, CREB-binding protein; CREB, cAMP-responsive element-binding protein 1; CRTC2, CREB-regulated transcription co-activator 2; DHAP, dihydroxyacetone phosphate; DKI, double knock-in; FOXO, Forkhead box O; G3P, glycerol-3-phosphate; GCGR, glucagon receptor; INSR, insulin receptor; LDH, lactate dehydrogenase; NEFA, nonesterified fatty acid; PC, pyruvate carboxylase; WAT, white adipose tissue;
Figure 1. Regulation of hepatic gluconeogenesis. Hepatic gluconeogenesis is regulated through allostery, substrate availability, redox balance, and gene expression. WAT lipolysis produces glycerol and NEFA, which can both independently stimulate hepatic gluconeogenesis. NEFA enters mitochondrial β-oxidation which produces acetyl-CoA, an allosteric activator of PC. PC catalyzes the conversion of pyruvate to oxaloacetate, which can directly enter the gluconeogenic pathway. On the other hand, glycerol is itself a gluconeogenic substrate. Glycerol from WAT lipolysis is phosphorylated to G3P and converted to DHAP, a gluconeogenic intermediate, by GPD2. The reaction catalyzed by GPD2 is dependent on cellular redox state and is inhibited by a high [NADH]:[NAD+] ratio. Similarly, gluconeogenesis from lactate is redox-regulated, because the conversion of lactate to pyruvate by LDH is inhibited by a high [NADH]:[NAD+] ratio. Transcriptional regulation of PCK1 and G6PC is coordinated by the opposing actions of glucagon and insulin. When insulin binds its receptor, AKT is activated and promotes nuclear exclusion of FOXO1, which decreases gluconeogenic gene expression. In contrast, glucagon binds the glucagon receptor and promotes IP3R-I-mediated ER Ca++ release. This in turn activates CRTC2, which forms a complex with CREB and CBP, and promotes transcriptional upregulation of PCK1 and G6PC. Abbreviations: CBP, CREB-binding protein; CREB, cAMP-responsive element-binding protein 1; CRTC2, CREB-regulated transcription co-activator 2; DHAP, dihydroxyacetone phosphate; DKI, double knock-in; FOXO, Forkhead box O; G3P, glycerol-3-phosphate; GCGR, glucagon receptor; INSR, insulin receptor; LDH, lactate dehydrogenase; NEFA, nonesterified fatty acid; PC, pyruvate carboxylase; WAT, white adipose tissue;CC BY · PubMed Central
Figure 2. Proposed mechanisms of metformin action. Complex I inhibition (top panel). Inhibition of complex I is central to several proposed mechanisms of metformin action. Following complex I inhibition, AMPK is activated by increased AMP levels, leading to inhibition of CRTC2 and preventing formation of the CREB-CBP-CRTC2 complex (orange boxes). AMPK also phosphorylates and inhibits ACC1 and 2, which promotes fat oxidation and decreases lipogenesis (purple boxes). Additionally, increased AMP is proposed to inhibit hepatic gluconeogenesis independently of AMPK. High AMP prevents glucagon-stimulated production of cAMP and therefore antagonizes hepatic glucagon action (pink boxes). AMP also allosterically inhibits FBP1, which directly inhibits the gluconeogenic pathway (blue boxes). Increased cytosolic redox (bottom panel). Metformin inhibition of GPD2 reduces the conversion of G3P to DHAP which impairs gluconeogenesis from glycerol and simultaneously increases the cytosolic [NADH]:[NAD+] ratio. LDH is inhibited by the increased [NADH]:[NAD+] ratio, thus reducing gluconeogenesis from lactate. Metformin inhibition of GPD2 is the only proposed mechanism that is independent of Complex I inhibition and produces substrate-selective inhibition of gluconeogenesis. Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, adenosine monophosphate–activated protein kinase; CBP, CREB-binding protein; CREB, cAMP-responsive element-binding protein 1; CRTC2, CREB-regulated transcription co-activator 2; DHAP, dihydroxyacetone phosphate; FBP, fructose 1,6-bisphosphatase; FDP, fructose 1,6-diphosphate; G3P, glycerol-3-phosphate; GLP-1, glucagon-like peptide-1; GPD, glycerol-3-phosphate dehydrogenase; LDH, lactate dehydrogenase; OCT1, organic cation transporter 1.
Figure 2. Proposed mechanisms of metformin action. Complex I inhibition (top panel). Inhibition of complex I is central to several proposed mechanisms of metformin action. Following complex I inhibition, AMPK is activated by increased AMP levels, leading to inhibition of CRTC2 and preventing formation of the CREB-CBP-CRTC2 complex (orange boxes). AMPK also phosphorylates and inhibits ACC1 and 2, which promotes fat oxidation and decreases lipogenesis (purple boxes). Additionally, increased AMP is proposed to inhibit hepatic gluconeogenesis independently of AMPK. High AMP prevents glucagon-stimulated production of cAMP and therefore antagonizes hepatic glucagon action (pink boxes). AMP also allosterically inhibits FBP1, which directly inhibits the gluconeogenic pathway (blue boxes). Increased cytosolic redox (bottom panel). Metformin inhibition of GPD2 reduces the conversion of G3P to DHAP which impairs gluconeogenesis from glycerol and simultaneously increases the cytosolic [NADH]:[NAD+] ratio. LDH is inhibited by the increased [NADH]:[NAD+] ratio, thus reducing gluconeogenesis from lactate. Metformin inhibition of GPD2 is the only proposed mechanism that is independent of Complex I inhibition and produces substrate-selective inhibition of gluconeogenesis. Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, adenosine monophosphate–activated protein kinase; CBP, CREB-binding protein; CREB, cAMP-responsive element-binding protein 1; CRTC2, CREB-regulated transcription co-activator 2; DHAP, dihydroxyacetone phosphate; FBP, fructose 1,6-bisphosphatase; FDP, fructose 1,6-diphosphate; G3P, glycerol-3-phosphate; GLP-1, glucagon-like peptide-1; GPD, glycerol-3-phosphate dehydrogenase; LDH, lactate dehydrogenase; OCT1, organic cation transporter 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Hill, The Vegetable System.
  2. World Health Organization, 2011, WHO model list of essential medicines

Cited by

See all 791

Metadata

Authors
LaMoia, T. E., & Shulman, G. I.
Affiliations
Yale University (US)
Corresponding author
Shulman, Gerald I
Venue
Endocrine Reviews
Published
2020-09-08
Volume
42
Issue
1
Pages
77-96
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W3084144806
Cited by
791
References
175
Citations by year
2026: 138 · 2025: 169 · 2024: 205 · 2023: 144 · 2022: 88 · 2021: 46 · 2020: 1
FWCI
6.68
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
U.S. Public Health Service (R01 DK114973, R01 DK113984, R01 DK116774, R01 DK119968, RC2 DK120534, P30 DK045735, GM007324)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
metformin, type 2 diabetes, hepatic gluconeogenesis, glucose-lowering effect, AMPK activation, mitochondrial complex I inhibition, glucose metabolism
MeSH terms
Animals, Diabetes Mellitus, Type 2, Gluconeogenesis, Glucose, Humans, Hypoglycemic Agents, Metformin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.